Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second autologous transplantation for multiple myeloma patients relapsing after the first autograft -- a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group.
Krivanová A, Hájek R, Krejcí M, Scudla V, Indrák K, Bacovský J, Büchler T, Svobodník A, Adam Z, Mayer J, Vorlícek J; Czech Myeloma Group. Krivanová A, et al. Among authors: scudla v. Onkologie. 2004 Jun;27(3):275-9. doi: 10.1159/000077977. Onkologie. 2004. PMID: 15249717 Clinical Trial.
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Krejci M, Scudla V, Tothova E, Schutzova M, Koza V, Adam Z, Krivanova A, Pour L, Buchler T, Sandecka V, Kralova D, Zahradova L, Vorlicek J, Mayer J, Hajek R. Krejci M, et al. Among authors: scudla v. Clin Lymphoma Myeloma. 2009 Dec;9(6):436-42. doi: 10.3816/CLM.2009.n.086. Clin Lymphoma Myeloma. 2009. PMID: 19951883
Low molecular weight heparins for thromboprophylaxis during induction chemotherapy in patients with multiple myeloma.
Kessler P, Pour L, Gregora E, Zemanova M, Penka M, Brejcha M, Adam Z, Bacovsky J, Fenclova M, Frankova H, Hausdorf P, Walterova L, Heinzova V, Holikova M, Krejci M, Kubackova K, Langrova E, Maisnar V, Meluzinova I, Stavarova Y, Straub J, Scudla V, Gumulec J, Ullrychova J, Hajek R; Czech Myeloma Group. Kessler P, et al. Among authors: scudla v. Klin Onkol. 2011;24(4):281-6. Klin Onkol. 2011. PMID: 21905619
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P, Zemanova Z, Kuglik P, Michalova K, Tajtlova J, Kaisarova P, Oltova A, Filkova H, Holzerova M, Balcarkova J, Jarosova M, Rabasova J, Hruba M, Spicka I, Gregora E, Adam Z, Scudla V, Maisnar V, Schutzova M, Hajek R; Czech Myeloma Group. Nemec P, et al. Among authors: scudla v. Leuk Lymphoma. 2012 May;53(5):920-7. doi: 10.3109/10428194.2011.634042. Epub 2011 Dec 13. Leuk Lymphoma. 2012. PMID: 22023516 Clinical Trial.
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Minarik J, Sandecka V, Maisnar V, Gregora E, Spicka I, Starostka D, Plonkova H, Jarkovsky J, Walterova L, Wrobel M, Adamova D, Pika T, Melicharova H, Pour L, Radocha J, Pavlicek P, Straub J, Gumulec J, Bacovsky J, Adam Z, Scudla V, Hajek R. Minarik J, et al. Among authors: scudla v. Leuk Res. 2013 Sep;37(9):1063-9. doi: 10.1016/j.leukres.2013.06.019. Epub 2013 Jul 8. Leuk Res. 2013. PMID: 23845888
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Minarik J, Pavlicek P, Pour L, Pika T, Maisnar V, Spicka I, Jarkovsky J, Krejci M, Bacovsky J, Radocha J, Straub J, Kessler P, Wrobel M, Walterova L, Sykora M, Obernauerova J, Brozova L, Gregora E, Adamova D, Gumulec J, Adam Z, Scudla V, Hajek R; Czech Myeloma Group. Minarik J, et al. Among authors: scudla v. PLoS One. 2015 Apr 14;10(4):e0123866. doi: 10.1371/journal.pone.0123866. eCollection 2015. PLoS One. 2015. PMID: 25875484 Free PMC article.
[Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W" Czech Myeloma Group].
Adam Z, Krejcí M, Bacovský J, Hejlová N, Kuca B, Svojgrová M, Franková H, Gumulec J, Janca J, Veprek K, Januska B, Lehanka F, Rezek Z, Praskac P, Cahová S, Vránová M, Papajík T, Králová E, Novotná J, Scudla V, Koza V, Drbal J, Faber E, Mareschová I, Hájek R, et al. Adam Z, et al. Among authors: scudla v. Vnitr Lek. 1998 Jul;44(7):400-8. Vnitr Lek. 1998. PMID: 9748876 Clinical Trial. Czech.
153 results